Deutsche Bank AG Has $2.52 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

Deutsche Bank AG increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 127.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 204,732 shares of the company’s stock after buying an additional 114,828 shares during the quarter. Deutsche Bank AG owned approximately 0.24% of Syndax Pharmaceuticals worth $2,516,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Virtus ETF Advisers LLC lifted its holdings in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after purchasing an additional 827 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth about $153,000. Guggenheim Capital LLC bought a new stake in shares of Syndax Pharmaceuticals during the 4th quarter worth about $157,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Syndax Pharmaceuticals during the 1st quarter worth about $162,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Syndax Pharmaceuticals in the 1st quarter valued at about $179,000.

Wall Street Analyst Weigh In

Several research firms recently commented on SNDX. Guggenheim restated a “buy” rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Citigroup increased their target price on shares of Syndax Pharmaceuticals from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research report on Tuesday, May 6th. BTIG Research boosted their price target on Syndax Pharmaceuticals from $43.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Finally, The Goldman Sachs Group assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, July 10th. They set a “buy” rating and a $18.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $38.00.

Syndax Pharmaceuticals Stock Performance

NASDAQ:SNDX opened at $15.40 on Wednesday. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $22.50. The company has a quick ratio of 4.55, a current ratio of 4.71 and a debt-to-equity ratio of 2.06. The stock’s 50-day simple moving average is $10.53 and its 200 day simple moving average is $11.90. The firm has a market capitalization of $1.33 billion, a PE ratio of -3.96 and a beta of 0.74.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.18. The firm had revenue of $37.96 million during the quarter, compared to analysts’ expectations of $26.64 million. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The business’s revenue for the quarter was up 984.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.80) earnings per share. On average, analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 19,200 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.84, for a total transaction of $304,128.00. Following the sale, the director owned 191,763 shares of the company’s stock, valued at approximately $3,037,525.92. The trade was a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael A. Metzger sold 7,534 shares of the stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total value of $69,990.86. Following the completion of the transaction, the chief executive officer owned 298,661 shares of the company’s stock, valued at $2,774,560.69. The trade was a 2.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,230 shares of company stock worth $684,527 in the last 90 days. Company insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).